Curriculum Vitae
John RICHARD Cochrane SAINSBURY
GMC 2379724 – Revalidation January 2016
Degrees:
1976 MBBS Newcastle upon Tyne
1981 FRCS (Eng)Royal College of Surgeons of England
1986 MD (with distinction)EGF receptors and Breast CancerNewcastle upon Tyne
1986 Certificate of Specialist TrainingRoyal College of Surgeons of England
PRIVATE PRACTICE ADMITTING RIGHTS
Harley St Clinic (HCA)
Princess Grace Hospital (HCA)
Spire Southampton Hospital
Spire Thames Valley Hospital
Mottistone Suite, IoW
SCOPE OF PRACTICE
I am an experienced breast surgeon and provide diagnostic and therapeutic services for patients with both benign and malignant breast disease. My practice includes reconstruction as well as other oncoplastic techniquesPlease refer to the Notes of Guidance for the format of publications listings.. I also perform augmentation and breast reductions.
PUBLICATIONS
Books – Authored
A Handbook of Diseases of the Breast. Dixon M and Sainsbury JRC. Churchill Livingstone, London and Edinburgh. 1993. 2nd edition 1998. 3rd edition in preparation
Books – Edited
The Key Sites Project (see grants obtained) resulted in published reports are now available to download as acrobat pdf documents from NYCRIS website ( I was on the editorial board responsible for these and wrote major parts of the breast one.
1. Central Nervous System(Dec 98)
2. Lung(July 99)
3. Melanoma(Dec 99)
4. Pancreas*(July 2000)
5. Colorectal(Dec 2000)
6. Breast(Dec 2001)
7. Cervix(May 2002)
8. Ovary(Dec 2002)
Books - Short Works
1985 Management decisions in breast cancer. ed. Basil A Stoll
Chapter 23. Growth factors and tumour stimulation. Harris AL and Sainsbury JRC
Blackwell/Moseby/Year Book Medical
1987 Biological bases for endocrine therapy in cancer. ed Basil A Stoll
Chapter 4. Growth factors and receptors as mediators of response. JRC Sainsbury
S. Karger, Basel, Switzerland
1987 The place of endocrine therapy in breast disease. ed A. Timothy
The prospects for new peptide hormone therapy. Sainsbury JRC
RSM Services Interantional Congress pp 51-55.
1987 Fourth UK Novantrone Symposium
Mitoxantrone and intraarterial treatment of breast cancer. Sainsbury JRC, Walker V and Ali HH pp 19-26
1991 Clinical Profiles of Care Workshop. Profiles of Care. Sainsbury JRC, Freer J and Brennan
NHS Resource Management Unit pp 3- 35
1994 ABC of Breast Diseases British Medical Journal. ed. JM Dixon
Chapters on: Early Breast Cancer
Prognostic Factors
Advanced Breast Cancer
Breast Reconstruction 2nd edition 2000
3rd edition 2005
4th edition 2011
1997 Management of Early Breast Cancer and Breast ReconstructionandTreatment of Advanced Stage Breast Cancer. Sainsbury JRC in Endocrine and Breast Surgery vol 5. Current Surgical Practice ed Farndon JR. Churchill Livingstone, Edinburgh
Revised and expanded 2000
1997 Benign breast disease
Sainsbury JRC in Crucial Controversies in Surgery 1998, ed Schein M and Wise L.
Karger Landes, Basel
1999 Sections on fibroadenoma, breast cyst and recurrent breast cancer.
Sainsbury JRC in Clinical Problems in Breast Disease eds. Dixon JM and Morrow M
Churchill Livingstone, Edinburgh
2002 Loco-regional management of breast cancer.
Sainsbury Richard In International Handbook of Breast Cancer ed SRD Johnston
Euromed Communications, London
2003 Recent developments in the endocrine therapy of early breast cancer.
Baum Michael and Sainsbury Richard
Recent Advances in Surgery 26 ed I Taylor and Johnstone C, London
2004 The Breast Chapter 55 in Bailey and Love’s Short Practice of Surgery 24th Edition
Ed Russell, RCG, Williams N and Bulstrode CJK, Arnold, London
2005 What can we expect from trials in the next 5 years? Ch 16 In Endocrine and Breast Surgery. Current Surgical Practice ed Dixon JM Richard Sainsbury
Churchill Livingstone, Edinburgh
2006 Breast operations Chapter 25 in Kirk RM Operative Textbook of General Surgery
Richard Sainsbury Churchill Livingstone
2007 Breast operations. Chapter 28 in Kirk RM Essential General Surgical Operations
Richard Sainsbury Elseiver
2008 The Breast Chapter (Chapter 52) in Bailey and Loves Short Practice of Surgery 25th Edition
Ed Williams N, Bulstrode CJK and O’Connell PR
2012The Breast Chapter (Chapter 50) in Bailey and Loves Short Practice of Surgery 26th Edition
Ed Williams N, Bulstrode CJK and O’Connell PR
2016 The Breast Chapter (Chapter 53) in Bailey and Loves Short Practice of Surgery 27th Edition
Ed Williams N, McCaskie A and O’Connell PR
Editorials– Journal
Intra arterial chemotherapy for breast cancer - where to now? (editorial)
Sainsbury R.
The Breast. 1992;1: 61
Biology of breast cancer in the under 40's
Sainsbury JRC
Pathologie Biologie 1992; 39: 839
Breast surgery - A maneagable specialty in the District Hospital
Lewis W, Donaldson K and Sainsbury JRC
The Breast 1994; 4: 24-26
Can all benign breast lumps be safely left in site? Consensus report from the Nottingham International Breast Meeting.
Sainsbury JRC
The Breast 1994; 3: 190-191
Upper limb disease in women treated for breast cancer (Signed commentary)
Sainsbury JRC
Lancet 1995; 346: 1444
Towards appropriate local surgery for patients with breast cancer.
Sainsbury R. Lancet 2000; 356:1124-5.
NICE: does guidance set the standard for good health care?
Sainsbury R
Lancet Oncol. 2009 Apr;10(4):315-6
Journal Papers - Academic Journals
These are divided into Laboratory Research, Health Service Research, Trials activity and other original Research, Reviews.
LABORATORY RESEARCH:
1.Epidermal growth factor receptors on human breast cancers.
Sainsbury JRC, Farndon JR, Sherbet GV and Harris AL
Brit J Surg 1985; 72: 186-188
2.Epidermal growth factor receptors are present in human bladder carcinoma - a comparison of invasive and superficial lesions.
Neal DE, Marsh CE, Bennett MK, Abel PD, Hall RR, Sainsbury JRC, et al.
Lancet 1985; i: 329: 366-368
3.Epidermal growth factor receptors and oestrogen receptors in human breast cancers.
Sainsbury JRC, Sherbet GV, Farndon JR and Harris AL
Lancet 1985; i: 329: 364-366
4.Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer.
Sainsbury JRC, Malcolm AJ, Appleton D, Farndon JR and Harris AL
J Clin Path 1985; 38: 1225-1228
5.Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer
Sainsbury JRC, Farndon JR, Needham GK, Malcolm AJ and Harris AL
Lancet 1987; i: 1398-1402
6.Prognostic factors in breast cancer: Immunohistochemical staining for SP1 and NCRC11 related to survival, tumour epidermal growth factor receptor and oestrogen receptor status.
Wright C, Angus B, Sainsbury JRC, et al.
J Path. 1987; 153: 325-331
7.Quantative assays of epidermal growth factor receptor in human breast cancer: cut off points of clinical relevance
Nicholson S, Sainsbury JRC, Needham GK, Chambers P, Farndon JR and Harris AL
Int J Cancer 1988; 42: 36-41
8.Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly post menopausal patients with breast cancer
Nicholson S, Halcrow P, Sainsbury JRC, Farndon JR and Harris AL
Br J Cancer 1988; 58: 810-814
9.Histological subtypes and epidermal growth factor receptor status of breast cancer
Sainsbury JRC, Nicholson S, Malcolm AJ, Farndon JR and Harris AL
Br J Cancer 1988; 58: 458-460
10.Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer
Nicholson S, Halcrow P, Farndon JR, Sainsbury JRC,Chambers P and Harris AL
Lancet 1989; i: 333:182-185
11.Expression of c-erb-B2 oncoprotein - a prognostic indicator in human breast cancer. ***
Wright C, Angus B, Nicholson, S, Sainsbury R, Cairns J, Gullick W, Kelly P, Harris AL, Horne CH.
Cancer Res 1989; 49: 2087-2090
12.Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breastcancer patients: neu and tamoxifen failure
Nicholson S, Wright C, Sainsbury JRC, et al.
J Steroid Biochem Molec Biol. 1990; 37: 811-814
13.Epidermal growth factor receptors and human breast cancer
Sainsbury JRC
Pathologie Biologie 1990; 38: 771-774
14.Epidermal growth factor receptor (EGFr): results of a six year follow up study in operable breast cancer with emphasis on the node negative subgroup
Nicholson S, Sainsbury JRC, Halcrow P, et al.
Brit J Cancer 1991; 63: 146-150
15.Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.
Wright C, Nicholson S, Angus B, Sainsbury JRC, et al.
Brit J Cancer 1992; 65: 118-121
16.Human breast cancer: prognostic significanceof the expression of the c-erb-B2 oncoprotein compared with epidermal growth factor receptor, ploidy and conventional pathologic features.
Gasparini G, Gullick W, Bevilacqua, P, Sainsbury JRC, et al.
JCO 1992; 10: 686-695
17.Epidermal growth factor receptor and other oncogenes as prognostic markers
Harris Al, Nicholson S, Sainsbury JRC, Wright A and Farndon J
JNCI 1992; 11: 181-187
18.The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers.
Robertson JFR, Jaeger W, Symendera JJ, Sainsbury JRC, Selby C, Coleman R, Howell A, Winstanley J, Jonssen PE, Bombardieri E.Gronberg H, Kumpulainen E, Blamey RW.
Europ J Canc 1999; 36: 47-53
19. DNA replication licensing and cell cycle kinetics of normal and neoplastic breast
Shetty A, Loddo M, Fanshawe T, Prevost, AT, Sainsbury R, Stoeber K and Williams G
Br J Cancer 2005; 93:1295-300
20.Ultra-Sensitive Immunoassays using Multi-Photon-Detection in Diagnostic Proteomics of Blood
Drukier AK, Ossetrova E, Schors E, Brown LR, Tomaszewski J, Sainsbury R, Godovac-Zimmermann J.Proteome Res 2005; 4:2375-8
21.Looking for Thom’s Biomarkers with Proteomics
DrukierAK, Grigoriev, I., Brown LR, Tomaszewski JE, Sainsbury R and Godovac-Zimmermann J
J Proteome Res. 2006; 5:2046-8.
22.High-Sensitivity Blood-Based Detection of Breast Cancer by Multi Photon Detection Diagnostic Proteomics
Drukier AK, Ossetrova N, Schors E, Krasik G, Grigoriev I, Koenig C, Sulkowski M, Holcman J, Brown LR, Tomaszewski JE, Schnall MD,Sainsbury R and Godovac-Zimmermann J
J Proteome Res. 2006; 5:1906-15.
23.Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer
M Loddo, S R Kingsbury, M Rashid, I Proctor, C Holt, J Young, S El-Sheikh, M Falzon, K L Eward, T Prevost, R Sainsbury, K Stoeber, G H Williams
British J Cancer 2009 Mar 24;100(6):959-70
24.Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53 mutant Her2 over-expressing and triple- receptor negative breast cancers.
Rodriguez S, Proctor I, Loddo M, Kingsbury S, Turdovic S, Sainsbury R, Stoeber K and Williams G
Am J Path 2010 October; 177 (4): 2034-2045
25. Pregnancy – associated plasma protein A regulates mitosis and is epigentically silenced in breast cancer.
Loddo, M, Andryszkiewicz, J, Rodriguez-Acebes, S, Stoeber, K, Jones, A, Dafou, D, Apostolidou, S, Wollenschlaeger, A, Widschwendter, M, Sainsbury, R, Tudzarova, S and Williams, GH
J. Pathol, 2014. 233: 344–356. doi: 10.1002/path.4393
HEALTH SERVICE RESEARCH
1.Popular marathons, half-marathons and other long distance runs: recommendations for medical support.
Tunstall-Pedoe D and Sainsbury JRC
BMJ 1894; 288: 1355-1359
2.Profound hypophosphataemia in patients collapsing after a fun run.
Dale G, Fleetwood A, Inkster JS and Sainsbury JRC
BMJ 1986; 292: 447-448
3.Fitness, unfitness and Phosphate
Dale G, Fleetwood A, Weddell A, Inkster JS and Sainsbury JRC
BMJ 1987; 294: 939-940
4.Does it matter where you live? Treatment variation for breast cancer in Yorkshire.
Sainsbury JRC, Johnston C, Rider L and MacAdam WFA
Brit J Cancer 1995; 71: 1275-1278
5.Survival from breast cancer. Influence of clinician workload and patterns of treatment on outcome.
Sainsbury JRC, Haward R, Rider L, Johnston C and Round C.
Lancet 1995; 345: 1265-1270
6.Morbidity of varicose vein surgery: auditing the benefit of changing clinical practice.
Miller GV, Lewis W, Sainsbury JRC and Macdonald RC
Annals Roy Coll Surg Engl 1996; 78: 345-349
7.Inequalities in breast cancer care and outcome.
Richards M, Sainsbury R and Kerr D
Brit J Cancer 1997; 76: 634-638
8.Effect on survival of delays in referral of patients with breast-cancer symptoms: a retrospective analysis
Sainsbury JRC, Johnston C and Haward RA
Lancet 1999; 353: 1132-1135
9.Measurement of degree of variation in the management of cancer - a new tool
Haward RA, Johnston C and Sainsbury JRC
Cancer Strategy 1999; 1: 65-72
10.The positive impact of research nurses on clinical trial recruitment
Poulter KM, Graham EH, Haining SA, Sainsbury JRC and Mason SA
BMJ 2001; 325: 124-5
11.Quality control in the locoregional treatment of breast cancer.
Rutgers EJTh, Blamey RW, Sainsbury JRC et al,
European J Cancer 2001; 37: 447-453
12.Is effective teamwork in breast cancer services associated with better clinical performance?
Amir Z, Borrill CS, Haward RA, Sainsbury R.
Psycho-oncology 2001; 10: 267-269
13.Breast cancer teams: the impact of constitution, new cancer workload, and methods of operation on their effectiveness
Haward R, Amir Z, Borrill C, Scully J, West M and Sainsbury R
Brit J Cancer 2003; 89: 15-22.
14.Surgeon workload and survival from breast cancer.
Stefoski Mikeljivec J, Haward R,Johnston C,Sainsbury R and Forman D
Brit J Canc 2003; 89: 487-491
15.Internal mammary node drainage and its role in sentinel node biopsy: The initial ALMANAC experience
Mansel RE, Newcombe RG, Shetty U, Sainsbury R et al
Clinical Breast Cancer 2004; 5: 279-284
16.Breast Cancer: Multidisciplinary care and clinical outcomes
Houssami N and Sainsbury R
Eur J Cancer, 2006; 42: 2480-2491
17.The challenge of evaluating annual mammography screening for young women with a family history of breast cancer.
The FH01 Management Committee, Steering Committee and Collaborators
J Med Screen 2006; 13: 177-182
18. Radiotherapy waiting times in breast cancer patients. A population-based cohort study
Jack RH, Davies E, Robinson D, Sainsbury R and Møller H
BMC Cancer 2007, 7:71
TRIALS ACTIVITY
1.Low dose aminoglutethimide (125mg twice daily) with hydrocortisone for thetreatment of advanced postmenopausal breast cancer.
Harris AL, Cantwell BMJ, Sainsbury JRC, et al.
Breast Cancer Res Treat. 1986; 7: 41-44
2.Endocrine effects of low dose aminoglutethimide with hydrocortisone - an optimal hormone supressive regimen
Harris AL, Dowsett M, Cantwell BMJ, Sainsbury JRC, et al.
Breast Cancer Res Treat. 1986; 7: 69-72
3.A dose escalation study of mitoxantrone given intra arterially for breast cancer
Sainsbury JRC, Walker V, Ali HH
Reg Cancer Treat. 1991; 3: 243-247
4.Results of the Cancer Research Campaign Adjuvant Trial for perioperative cyclophosphamide and long-term tamoxifen in early breast cancer reported at the tenth year of follow up.
Baum M, Houghton J, Sainsbury JRC et al.
Acta Oncol 1992; 31: 251-257
5. The effects of adjuvant tamoxifen: the latest results from the Cancer Research Campaign Adjuvant Breast Trial.
Cancer Research Campaign Breast Cancer Trials Group
Eur J Cancer 1992; 28:904-907
6.The role of radiotherapy following total mastectomy in patients with early breast cancer.
Houghton J, Baum M, Sainsbury JRC et al.
Eur J Cancer 1993; 30: 342-347
7.Role of radiotherapy following total mastectomy in patients with early breast cancer.
Houghton J, Baum M, Haybittle J, Sainsbury JRC et al
World J Surg 1994; 18: 117-122
8.Seven-year follow up on 334 patients treated by breast conserving surgery and short course radical postoperative radiotherapy: a report of the Yorkshire Breast Cancer Group.
Ash DV, Benson EA, Sainsbury JRC, Round C and Head C.
Clinical Oncology 1995; 7: 93-96
9.Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled randomized clinical trial in postmenopausal patients.
Dowsett M, BundredNJ, Decensi A, Sainsbury JRC et al.
Cancer Epidemiology Biomarkers and Prevention 2001; 10: 61-966
10.Pharmacokinetics of anastrazole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in post-menopausal women: a sub-protocol of the ‘Arimidex and Tamoxifen alone or in Combination’ (ATAC) trial.
Baum M, Dowsett M, .....Sainsbury R et al.
Brit J Cancer 2001; 85: 317-324
11.Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post menopausal women with early breast cancer: first results of the ATAC randomised trial.
The ATAC Trialists Group Lancet 2002; 359: 2131-39
12.Maintenance therapy with subcutaneous recombinant Beta Interferon, after response to chemotherapy in metastatic breast cancer.
Stark D, Joffee J, Rodwell S, Sainsbury R and Perrin T
The Breast 2003; 15:212-218
13.Intraoperative radiotherapy for breast cancer.
Vaidya J, Tobias JS, Baum M, Keshtgar M, Joseph D, Wenz F, Houghton J, Saunders C, Corica T, D'Souza D, Sainsbury R, Massarut S, Taylor I, Hilaris B. et al
Lancet Oncology 2004; 5: 165-173
14.A randomized multicenter study of gamolenic acid (Efamast) with and without antioxidant vitamins and minerals in the management of mastalgia.
Goyal A, Mansel R, Sainsbury R et al
The Breast Journal 2005; 11: 41-47
15.Adjuvant goserelin in premenopausal patients with early breast cancer: results from the ‘Zoladex’ in premenopausal patients (ZIPP) trial
Baum M, Houghton J, Hackshaw A, Rutqvist , Fornander T, Nordenskjold B, Nicolucci A, Sainsbury Rfor ZIPP International Collaborators Group
Eur J Cancer 2006; 42: 895-904
16.Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status
Dowsett M, HoughtonJ, IdenC, Salter J, Farndon J, A’HernR, SainsburyR, Baum M
Annals of Oncology 2006; 17: 818 - 826.
17.Timing of breast cancer surgery in relation to menstrual cycle phase: no effect on 3-year prognosis: The ITS Study
H Thorpe, S R Brown, J R Sainsbury, T J Perren, V Hiley, M Dowsett, A Nejim, J M Brown
British Journal of Cancer 2007: 98, 39 - 44
18.Targetted intraoperative radiotherapy (Targit) yields very low recurrence rates when given as a boost.
Vaidya J, Baum M, Tobias JS, Massarut S, Wenz F, Murphy O, Hilaris B, Houghton J, Saunders C, Corica T, Roncadin M, Kraus-Tiefenbacher U, Melchaert F, Keshtgar M, Sainsbury R,Douek M, Harrison E, Thompson A, Joseph D
Int J Radiat Oncol Biol Phys. 2006; 66:1335-8
19. Use of LHRH-agonists as adjuvant treatment in pre-menopausal patients with hormone receptor-positive breast cancer: an overview of the randomised adjuvant trials
LHRH-agonists in Early Breast Cancer Overview group.
Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, Sainsbury R
Lancet 2007; 369: 1711-23
20.Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer
Allan Hackshaw , Michael Baum , Tommy Fornander , Bo Nordenskjold , Antonio Nicolucci , Kathryn Monson, Sharon Forsyth , Krystyna Reczko , Ulla Johansson , Helena Fohlin, Miriam Valentini , Richard Sainsbury
J Natl Cancer Inst. 2009 Mar 4;101(5):341-9.
- Long-term benefits of 5 years of tamoxifen: 10 year follow up of a large randomised trial in women aged at least 50 years with early breast cancer.
Allan Hackshaw, Michael Roughton, Sharon Forsyth, Kathryn Monson, Krystyna Reczko, Richard Sainsbury, Michael Baum
J Clin Oncol2011 29(13), 1657-1663
22. Tumour characteristics and projected effect on mortality of mammographic surveillance in women aged under 50 years with a family history of breast cancer (FH01 study): a prospective single-arm study.
FH01 study group
Lancet Oncology 2010; 11: 1127-34
OTHER ORIGINAL RESEARCH
1.Macrophage infiltration of breast tumours: A prospective study
Lauder I, Aherne W, Stewart J and Sainsbury JRC.
J Clin Path 1977; 30: 563-568
2.Plasma cortisol levels: A comparison between sick patients and volunteers given intravenous cortisol.
Sainsbury JRC, Stoddart JC and Watson MJ.
Anaesthesia 1981; 36: 16-21
3.Presence of epidermal growth factor in high concentrations in human benign cysts of the breast.
Porteous C, Geoorge WD, Sainsbury JRC, Dgago-Jack S and Pragnall IB
Scot Med J 1986; 212: 45-47
4.The natural history of the benign breast lump
Sainsbury JRC, Nicholson S, Needham GK, Wadhera V and Farndon JR
Brit J Surg 1988; 75: 1080-1082
5.The use of fine needle aspiration biopsy cytology with immediate reporting in breast disease
Nicholson S, Sainsbury JRC, Needham GK, Wadhera V and Farndon JR8
Brit J Surg 1988; 75: 847-850
6.Beta-endorphin - a factor in fun run collapse?
Dale G, Fleetwood A, Weddell A, Ellis RD and Sainsbury JRC
BMJ 1987; 294: 1004-1005
7.A better nipple prosthesis
Sainsbury JRC, Walker V and Smith P